At this time, we are prospectively investigating the efficacy and safety of osimertinib for elderly patients ≥75 years old with ineffective prior EGFR-TKI treatment or with recurrence in EGFR-TKI mutation-positive and T790M mutation-positive nonsmall-cell lung cancer (NSCLC). Here, EGFR is linked to lung cancer.